OR WAIT null SECS
September 26, 2016
FDA has approved Amgen's Amjevita as a biosimilar to AbbVie's Humira for multiple inflammatory diseases.
“This is the fourth FDA-approved biosimilar. The biosimilar pathway is still a new frontier and one that we expect will enhance access to treatment for patients with serious medical conditions,” said Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research.
Amjevita is approved for the following indications in adult patients: